Azevedo GD, Franco RF, Baggio MS, Maranhão TMDO, Sá MFSD. Procoagulant state after raloxifene therapy in postmenopausal women.
Fertil Steril 2005;
84:1680-4. [PMID:
16359964 DOI:
10.1016/j.fertnstert.2005.06.029]
[Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2005] [Revised: 06/05/2005] [Accepted: 06/05/2005] [Indexed: 11/21/2022]
Abstract
OBJECTIVE
To investigate the effects of raloxifene on the hemostatic system in postmenopausal women.
DESIGN
A prospective longitudinal study.
SETTING
Outpatient clinic of the Faculty of Medicine of Ribeirão Preto, Brazil.
PATIENT(S)
Sixteen postmenopausal women aged 56.8 +/- 5.9 years (mean +/- SD).
INTERVENTION(S)
Raloxifene hydrochloride (60 mg once daily) was administered orally for a period of 6 months.
MAIN OUTCOME MEASURE(S)
Plasma activities of coagulation factors (II, V, VII, VIII, IX, X, XI, XII, and fibrinogen), prothrombin-derived fragment 1+2, and activated protein C (APC) sensitivity ratio were measured at baseline and after 1, 3, and 6 months of treatment.
RESULT(S)
Factor VIII activity increased by 17.1% and 26.9% at 3 and 6 months of treatment, respectively, compared with baseline. Factor XI and FXII activities significantly increased by 10.9% and 43.1%, respectively, after 6 months compared with baseline. A significant reduction of APC sensitivity ratio also was observed after 6 months of treatment.
CONCLUSION(S)
A procoagulant state characterized by increased factor VIII, XI, and XII plasma levels and by reduced APC sensitivity was observed after raloxifene therapy in post-menopausal women.
Collapse